Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 2155-2163, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hancock, D. K.
Right arrow Articles by Levin, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hancock, D. K.
Right arrow Articles by Levin, B. C.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2002;48:2155-2163.)
© 2002 American Association for Clinical Chemistry, Inc.

Design and Use of a Peptide Nucleic Acid for Detection of the Heteroplasmic Low-Frequency Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) Mutation in Human Mitochondrial DNA

Diane K. Hancock1, Frederick P. Schwarz1, Fenhong Song2, Lee-Jun C. Wong3 and Barbara C. Levin1a

1 Biotechnology Division, National Institute of Standards and Technology, Gaithersburg, MD 20899.

2 University of Maryland Biotechnology Institute, Center for Advanced Research in Biotechnology, Rockville, MD 20850.

3 Institute for Molecular and Human Genetics, Georgetown University Medical Center, Washington, DC 20007.

aAddress correspondence to this author at: 100 Bureau Dr., MS 8311, National Institute of Standards and Technology, Gaithersburg, MD 20899-8311. Fax 301-975-8505; e-mail barbara.levin{at}nist.gov.

Background: Most pathogenic human mitochondrial DNA (mtDNA) mutations are heteroplasmic (i.e., mutant and wild-type mtDNA coexist in the same individual) and are difficult to detect when their concentration is a small proportion of that of wild-type mtDNA molecules. We describe a simple methodology to detect low proportions of the single base pair heteroplasmic mutation, A3243G, that has been associated with the disease mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) in total DNA extracted from blood.

Methods: Three peptide nucleic acids (PNAs) were designed to bind to the wild-type mtDNA in the region of nucleotide position 3243, thus blocking PCR amplification of the wild-type mtDNA while permitting the mutant DNA to become the dominant product and readily discernable. DNA was obtained from both apparently healthy and MELAS individuals. Optimum PCR temperatures were based on the measured ultraviolet thermal stability of the DNA/PNA duplexes. The presence or absence of the mutation was determined by sequencing.

Results: In the absence of PNAs, the heteroplasmic mutation was either difficult to detect or undetectable by PCR and sequencing. Only PNA 3 successfully inhibited amplification of the wild-type mtDNA while allowing the mutant mtDNA to amplify. In the presence of PNA 3, we were able to detect the heteroplasmic mutation when its concentration was as low as 0.1% of the concentration of the wild-type sequence.

Conclusion: This methodology permits easy detection of low concentrations of the MELAS A3243G mutation in blood by standard PCR and sequencing methods.




The following articles in journals at HighWire Press have cited this article:


Home page
J. Mol. Diagn.Home page
B. Gilje, R. Heikkila, S. Oltedal, K. Tjensvoll, and O. Nordgard
High-Fidelity DNA Polymerase Enhances the Sensitivity of a Peptide Nucleic Acid Clamp PCR Assay for K-ras Mutations
J. Mol. Diagn., July 1, 2008; 10(4): 325 - 331.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Ogasawara, K. Nakayama, M. Tarnowka, J. P. McCoy Jr, S. Kajigaya, B. C. Levin, and N. S. Young
Mitochondrial DNA spectra of single human CD34+ cells, T cells, B cells, and granulocytes
Blood, November 1, 2005; 106(9): 3271 - 3284.
[Abstract] [Full Text] [PDF]


Home page
Appl. Environ. Microbiol.Home page
S. J. Green and D. Minz
Suicide Polymerase Endonuclease Restriction, a Novel Technique for Enhancing PCR Amplification of Minor DNA Templates
Appl. Envir. Microbiol., August 1, 2005; 71(8): 4721 - 4727.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Urata, Y. Wada, S. H. Kim, W. Chumpia, Y. Kayamori, N. Hamasaki, and D. Kang
High-Sensitivity Detection of the A3243G Mutation of Mitochondrial DNA by a Combination of Allele-Specific PCR and Peptide Nucleic Acid-Directed PCR Clamping
Clin. Chem., November 1, 2004; 50(11): 2045 - 2051.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.